FDA Clears Non-Invasive AI Device for Skin Cancer Detection
Source: Cancer Network, January 2024
The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.
The FDA has granted clearance to DermaSensor’s artificial intelligence (AI)–powered tool for evaluating skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma, according to a press release from DermaSensor Inc.
Developers designed the spectroscopy technology to help physicians non-invasively assess the cellular and subcellular features of a lesion suspected to confer skin cancer. By acting on an FDA-cleared algorithm, the AI-based tool can generate an immediate, objective result for a diagnosis. The device’s mechanism is believed to assist practices reduce reliance on clinical training and subjective judgment that are otherwise necessary for assessing suspicious moles or lesions with the naked eye or standard magnified visual examination.